We posit that blockade of IL-12/IL-23 axis as treatment strategy to halt the progression of small aneurysms merits further consideration given the availability of the immunotherapeutics in the clinic combined with the observation that IL-12p40 and IL-23p19 are abundantly expressed in human AAA tissue. The gene discussed is IL23A; the disease is aneurysm.